Stocks expected to have increasing option volume: SRPT CCL SATS X
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
- Oppenheimer sees AI software winners as focus shifts to ROI
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
Sarepta Therapeutics (SRPT) PT Lowered to $28 at Evercore ISI
June 17, 2025 4:02 PM EDTEvercore ISI analyst Gavin Clark-Gartner lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $28.00 (from $50.00) while maintaining a In Line rating.
The analyst comments "Following the second recent Elevidys-related death due to liver failure, were reiterating our In-Line rating and lowering our PT to $28/sh. See our previous downgrade note for more details on the broader setup. Some thoughts on the path forward: Tough to... More
Goldman Sachs Downgrades Sarepta Therapeutics (SRPT) to Neutral
June 17, 2025 7:14 AM EDTGoldman Sachs analyst Salveen Richter downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Buy to Neutral with a price target of $29.00.
The analyst comments "We downgrade SRPT to Neutral from Buy as we see an uncertain outlook amidst safety concerns, following the second reported death of a non-ambulatory Elevidys-treated Duchenne muscular dystrophy patient due to acute liver failure (ALF). SRPT plans to convene a Duchenne and liver health expert panel to consider enhanced immunosuppression, as the company believes that adding... More
Morgan Stanley Downgrades Sarepta Therapeutics (SRPT) to Equalweight
June 16, 2025 2:47 PM EDTMorgan Stanley analyst Matthew Harrison downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Overweight to Equalweight with a price target of $40.00 (from $113.00).
The analyst comments "Second patient death raises concerns as use in non-ambulatory patients restricted (commercial and clinical), while enhanced immunosuppressive regimen in development... More
BMO Capital on Sarepta (SRPT) Following Earlier Downgrade: 'we believe management could potentially turn the story around'
June 16, 2025 11:07 AM EDTBMO Capital analyst Kostas Biliouris reiterated a Market Perform rating and $70.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "Management is taking all the right/necessary measures to understand the recent non-ambulatory patient deaths and prevent future ambulatory/non-ambulatory deaths. Given the significant... More
